Bgh
BGH Capital is an independent private equity firm headquartered in Melbourne that invests in mid-market companies in Australia and New Zealand. It states a focus on attractive fundamentals, growing end markets and operational value creation.
What stands out about Bgh
BGH Capital publicly describes a mid-market investment focus in Australia and New Zealand, with sector coverage spanning healthcare, consumer, financial services, business services, education, technology, leisure and industrials. Its stated approach includes value-creation planning, operational resources, management alignment, responsible investing and risk management.[1][2][3][4][10]
What does Bgh invest in?
BGH Capital is an independent private equity firm founded in 2017 by Robin Bishop, Ben Gray and Simon Harle and headquartered in Melbourne, Australia. It provides portfolio companies with capital, analytical, strategic and operational resources and capability.
The firm’s current homepage states A$7.6 billion in funds under management, 16 portfolio company investments, 11 partners and 60 team members.[1][3]
BGH Capital states that it invests in mid-market companies in Australia and New Zealand with attractive fundamentals and growing end markets. Its described approach includes differentiated sourcing, value-creation planning, operational expertise, alignment, responsible investing and risk management.[2]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Bgh?
An owner evaluating BGH Capital can clarify the firm’s current equity investment range and enterprise-value range, preferred ownership position, mix of primary growth capital and secondary liquidity, management rollover expectations, governance and reporting requirements, and the operating resources that would be assigned to the company.
Because BGH Capital’s official Portfolio page does not provide deal-level names or terms in its page text, an owner can also request references from current and exited portfolio-company management teams, recent realized and unrealized investment examples, expected investment horizon and exit options, transaction fees, financing expectations, exclusivity terms and diligence costs.[1][2][10]
Does BGH Capital prefer control, significant minority or flexible ownership positions
What percentage of the investment is primary growth capital versus secondary liquidity
What companies does Bgh target?
BGH Capital states that it targets mid-market businesses with strong or attractive fundamentals and growing end markets that support attractive returns.
The public materials described here do not establish a specific equity investment range, enterprise-value range, profitability threshold or ownership preference.[2]
BGH Capital publicly lists Healthcare & Aged Care; Consumer Products & Services; Financial Services; Business Services; Education; Technology, Media & Telecom; Leisure, Tourism & Hospitality; and Industrials as sectors of focus.[2]
BGH Capital invests in businesses in Australia and New Zealand and is headquartered in Melbourne, Australia.[1]
The public materials described here do not establish a separate platform-versus-add-on investment framework.
BGH Capital’s official Portfolio page displays a Portfolio heading but does not disclose identifiable portfolio-company names, transaction dates, transaction values, ownership percentages or consideration terms in its page text.[10]
BGH Capital, as manager or adviser to BGH Capital Fund II, entered binding agreements to acquire 100% of Aspen Asia Pacific excluding China for R26.5 billion. The Aspen announcement describes this as a proposed transaction and does not disclose a final completion date or final transaction consideration beyond the announced R26.5 billion proposed divestment price.
A Sixth Street and BGH Capital consortium agreed to acquire all Pushpay shares under a scheme of arrangement at NZ$1.34 per share in cash, with an implied equity value of NZ$1,539 million and enterprise value of US$933 million. BGH Capital also announced an increased offer price of A$8.15 per share in its off-market takeover offer for Virtus Health on May 24, 2022.
A consortium comprising BGH Capital and the Trouchet family interests entered a confidentiality agreement on July 3, 2026, after Tourism Holdings granted due-diligence access in relation to a potential acquisition at an indicative offer of no less than NZ$3.10 per share. The Tourism Holdings announcement describes due-diligence access and an indicative offer rather than a completed acquisition.[4][5][6][7]
What is not clear from Bgh's public investment criteria?
BGH Capital’s official Portfolio page does not disclose identifiable portfolio-company names, transaction dates, transaction values, ownership percentages or consideration terms in its page text.
The Aspen Pharmacare announcement describes a proposed transaction and does not disclose a final completion date or final transaction consideration beyond the announced R26.5 billion proposed divestment price.[4][10]
Questions to ask when evaluating Bgh as a buyer or investment partner
What equity investment range and enterprise-value range does BGH Capital currently target?
Does BGH Capital prefer control, significant minority or flexible ownership positions?
What percentage of the investment is primary growth capital versus secondary liquidity?
What management rollover, governance, board and reporting requirements apply?
Which operating resources would be assigned to the company?
What are the expected investment horizon and exit options?
Can BGH Capital provide references from current and exited portfolio-company management teams?
Sources & research notes
- Official website / firm overview
- Investment strategy
- Transaction size / criteria
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
- Structure / regulatory context
- Public disclosure information
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.